- Home
- MIRM vs MTN Comparison
MIRM vs MTN Comparison
Compare MIRM & MTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- MTN
- Stock Information
- Founded
- MIRM 2018
- MTN 1997
- Country
- MIRM United States
- MTN United States
- Employees
- MIRM N/A
- MTN N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- MTN Services-Misc. Amusement & Recreation
- Sector
- MIRM Health Care
- MTN Consumer Discretionary
- Exchange
- MIRM Nasdaq
- MTN Nasdaq
- Market Cap
- MIRM 2.5B
- MTN 5.8B
- IPO Year
- MIRM 2019
- MTN 1997
- Fundamental
- Price
- MIRM $50.30
- MTN $164.02
- Analyst Decision
- MIRM Strong Buy
- MTN Hold
- Analyst Count
- MIRM 9
- MTN 10
- Target Price
- MIRM $66.22
- MTN $186.50
- AVG Volume (30 Days)
- MIRM 468.1K
- MTN 922.8K
- Earning Date
- MIRM 08-06-2025
- MTN 06-05-2025
- Dividend Yield
- MIRM N/A
- MTN 5.41%
- EPS Growth
- MIRM N/A
- MTN 6.60
- EPS
- MIRM N/A
- MTN 7.74
- Revenue
- MIRM $379,251,000.00
- MTN $2,958,444,000.00
- Revenue This Year
- MIRM $35.83
- MTN $3.77
- Revenue Next Year
- MIRM $16.83
- MTN $3.71
- P/E Ratio
- MIRM N/A
- MTN $21.19
- Revenue Growth
- MIRM 69.31
- MTN 2.38
- 52 Week Low
- MIRM $33.52
- MTN $129.85
- 52 Week High
- MIRM $54.23
- MTN $199.45
- Technical
- Relative Strength Index (RSI)
- MIRM 59.09
- MTN 66.00
- Support Level
- MIRM $47.89
- MTN $154.93
- Resistance Level
- MIRM $51.93
- MTN $158.62
- Average True Range (ATR)
- MIRM 1.49
- MTN 3.97
- MACD
- MIRM -0.25
- MTN 0.69
- Stochastic Oscillator
- MIRM 59.65
- MTN 96.91
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About MTN Vail Resorts Inc.
Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.